INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.680
+0.040 (2.44%)
Jan 22, 2026, 2:57 PM EST - Market open
INmune Bio Market Cap
INmune Bio has a market cap or net worth of $44.66 million as of January 22, 2026. Its market cap has decreased by -61.96% in one year.
Market Cap
44.66M
Enterprise Value
16.95M
1-Year Change
-61.96%
Ranking
Category
Stock Price
$1.68
Market Cap Chart
Since February 4, 2019, INmune Bio's market cap has decreased from $77.82M to $44.66M, a decrease of -42.61%. That is a compound annual growth rate of -7.66%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 21, 2026 | 43.60M | 5.13% |
| Dec 31, 2025 | 41.47M | -59.95% |
| Dec 31, 2024 | 103.55M | -48.97% |
| Dec 29, 2023 | 202.92M | 78.35% |
| Dec 30, 2022 | 113.78M | -37.49% |
| Dec 31, 2021 | 182.00M | -21.41% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Feb 4, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Anebulo Pharmaceuticals | 44.78M |
| Galecto | 44.61M |
| CEL-SCI | 44.15M |
| Tvardi Therapeutics | 43.44M |
| Apollomics | 43.20M |
| Jasper Therapeutics | 43.10M |
| Cingulate | 42.39M |
| Xilio Therapeutics | 42.28M |